Continued use of TNF blockers during pregnancy is not linked to adverse fetal or obstetric outcomes, according to a press release from the American College of Rheumatology (ACR). In a study presented by Molto et al at ACR Convergence 2023, investigators used the nationwide French health insurance database to analyze the outcomes of 2,000 pregnant patients with rheumatoid arthritis or spondyloarthritis who received TNF inhibitors from 2008 to 2017. Among the patients involved in the study, 1,497 of them discontinued treatment upon learning of their pregnancy. The investigators reported no statistically significant differences in poor obstetric, fetal, or infant outcomes—including spontaneous abortion, medical termination of pregnancy, preeclampsia, eclampsia, gestational diabetes, preterm birth, small birth weight, or major birth defects—between those who continued or discontinued treatment with TNF inhibitors. Further, compared with those who discontinued treatment, the patients who continued TNF inhibitors were less likely to be hospitalized with severe infections during pregnancy. “[These findings] contribute to the increasingly reassuring data on the use of TNF [inhibitors] during pregnancy,” concluded lead study author Anna Molto, MD, PhD, HDR, a rheumatologist and researcher at the Cochin Hospital in Paris.